Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours

AIMS: This phase I study evaluated the effects of the moderate cytochrome P450 (CYP) 3A inhibitor fluconazole and the strong CYP3A/P‐glycoprotein (P‐gp) inhibitor itraconazole on the pharmacokinetics of the investigational neural precursor cell expressed, developmentally downregulated 8 (NEDD8)‐acti...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Clin Pharmacol
Prif Awduron: Faessel, Hélène, Nemunaitis, John, Bauer, Todd M., Lockhart, A. Craig, Faller, Douglas V., Sedarati, Farhad, Zhou, Xiaofei, Venkatakrishnan, Karthik, Harvey, R. Donald
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2019
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6595297/
https://ncbi.nlm.nih.gov/pubmed/30845347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13915
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg